ALACT Acticor Biotech

Regulatory News:

ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 62,031 shares - € 191,956.52 - Number of executions on buy side on semester: 264 - Number of executions on sell side on semester: 42 - Traded volume on buy side on semester: 67,876 shares for € 445,195.95 - Traded volume on sell side on semester: 5,845 shares for € 37,412.21

As a reminder the following resources appeared on the liquidity account when the activity started:

- 0 shares - € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.

Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For further information, please go to www.acticor-biotech.com

Appendix

 

Buy Side

 

Sell Side

 

Number of executions

Number of shares

Traded volume in EUR

 

Number of executions

Number of shares

Traded volume in EUR

Total

264

67 876

445 195.95

 

42

5 845

37 412.21

01/11/2021

37

26 763

189 214.41

 

-

-

-

02/11/2021

10

4 977

34 639.92

 

-

-

-

03/11/2021

22

4 799

33 113.10

 

-

-

-

04/11/2021

14

3 224

21 697.52

 

-

-

-

05/11/2021

3

450

3 006.00

 

5

1 500

10 950.00

08/11/2021

-

-

-

 

8

1 500

10 470.00

09/11/2021

5

1 000

6 850.00

 

4

23

161.00

10/11/2021

7

1 000

6 870.00

 

-

-

-

11/11/2021

4

500

3 415.00

 

-

-

-

12/11/2021

3

358

2 445.14

 

1

1

6.95

15/11/2021

1

142

969.86

 

-

-

-

16/11/2021

10

3 509

23 510.30

 

-

-

-

17/11/2021

4

896

5 850.88

 

-

-

-

18/11/2021

10

1 000

6 640.00

 

1

2

13.40

19/11/2021

15

2 650

16 748.00

 

1

1

6.60

22/11/2021

-

-

-

 

3

801

5 286.60

23/11/2021

1

400

2 600.00

 

1

1

6.60

24/11/2021

4

400

2 592.00

 

1

9

59.40

26/11/2021

6

1 201

7 710.42

 

2

161

1 046.50

29/11/2021

6

950

5 918.50

 

-

-

-

30/11/2021

10

1 100

6 677.00

 

-

-

-

01/12/2021

1

1

5.90

 

-

-

-

02/12/2021

9

1 270

7 442.20

 

1

1

5.98

03/12/2021

2

2

11.40

 

-

-

-

06/12/2021

8

328

1 869.60

 

-

-

-

07/12/2021

13

1 060

5 808.80

 

-

-

-

08/12/2021

7

1 325

7 155.00

 

-

-

-

09/12/2021

-

-

-

 

3

401

2 245.60

10/12/2021

2

124

669.60

 

2

501

2 755.50

14/12/2021

7

1 392

7 516.80

 

-

-

-

15/12/2021

4

400

2 120.00

 

-

-

-

16/12/2021

7

801

4 213.26

 

1

1

5.30

17/12/2021

8

1 445

7 239.45

 

-

-

-

20/12/2021

3

800

3 944.00

 

-

-

-

21/12/2021

2

555

2 680.65

 

-

-

-

22/12/2021

5

500

2 365.00

 

-

-

-

23/12/2021

7

1 000

4 570.00

 

-

-

-

24/12/2021

-

-

-

 

2

400

1 880.00

29/12/2021

5

1 000

4 590.00

 

1

200

932.00

30/12/2021

1

500

2 280.00

 

2

238

1 097.18

31/12/2021

1

54

246.24

 

3

104

483.60

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005057/en/

ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD General Manager and CSO Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38 13

NewCap Mathilde BOHIN / Olivier BRICAUD Investor Relations acticor@newcap.eu T. : +33 (0)1 44 71 94 95